Status
Conditions
Treatments
About
This is a single-center, phase IIT clinical trial to evaluate autologous regenerative islet transplantation for insulin-dependent diabetes mellitus.
Twenty patients with insulin-dependent diabetes mellitus will be enrolled: poor blood glucose control despite intensive exogenous insulin therapy. The primary endpoint will be defined by the return to normal blood glucose control without insulin at 12 months after transplantation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Insulin-dependent diabetes mellitus, the specific criteria are (1 of 4-6 is sufficient).
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Hao Yin
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal